Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

415
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
415
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

122
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
122
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

358
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
358
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

78
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

328
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
328
  1. Home
  3. Research Domains
  5. Agricultural, Veterinary And Food Sciences
  7. Agriculture, Land And Farm Management
  9. Agricultural Production Systems Simulation
  11. Unveiling The Unexplored Multifactorial Potential Of 5-aminosalicylic Acid In Diabetic Wound Therapy

Unveiling the Unexplored Multifactorial Potential of 5-Aminosalicylic Acid in Diabetic Wound Therapy

Bharat Kumar Reddy Sanapalli1, Ashwini Deshpande2, Vidyasrilekha Sanapalli3

  • 1Department of Pharmacology, School of Pharmacy and Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-be-University, Jadcherla 509301, Hyderabad, India.

Diseases (Basel, Switzerland)
|August 28, 2024

Related Experiment Videos

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
04:09

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

2.8K
Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds
10:49

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds

Published on: August 21, 2021

4.4K
Protocol to Create Chronic Wounds in Diabetic Mice
06:55

Protocol to Create Chronic Wounds in Diabetic Mice

Published on: September 25, 2019

20.2K

View abstract on PubMed

Summary
This summary is machine-generated.

Investigating 5-aminosalicylic acid (5-ASA) for diabetic wounds (DWs) shows potential. Activating PPAR-γ and TGF-β pathways may improve insulin sensitivity and healing in diabetic patients.

Area of Science:

  • Biomedical Science
  • Pharmacology
  • Wound Healing Research

Background:

  • Diabetic wounds (DWs) are chronic complications of type 2 diabetes mellitus (DM), stemming from inflammation, oxidation, and impaired tissue repair.
  • Current DW treatments focus on pressure relief, debridement, and infection control, often failing to address underlying pathophysiology.
  • Insulin resistance and sensitivity are central to DW development, impacting microcirculation and tissue regeneration.

Purpose of the Study:

  • To explore the potential therapeutic benefits of 5-aminosalicylic acid (5-ASA) for treating diabetic wounds.
  • To investigate the role of 5-ASA in activating peroxisome proliferator-activated receptor gamma (PPAR-γ) and transforming growth factor beta (TGF-β) via the AhR pathway in DWs.
  • To assess the impact of 5-ASA on insulin sensitivity, re-epithelialization, and microcirculation in the context of DWs.
Keywords:
5-aminosalicylic acidPPAR-γ activationTGF-β activationdiabetic wounds

Related Experiment Videos

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
04:09

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

2.8K
Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds
10:49

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds

Published on: August 21, 2021

4.4K
Protocol to Create Chronic Wounds in Diabetic Mice
06:55

Protocol to Create Chronic Wounds in Diabetic Mice

Published on: September 25, 2019

20.2K

Main Methods:

  • Speculative analysis based on existing evidence regarding 5-ASA, PPAR-γ, and TGF-β pathways.
  • Highlighting the need for stabilized 5-ASA formulations with enhanced skin permeability and absorption rates.
  • Proposing in vitro and in vivo studies using stabilized 5-ASA formulations and placebo controls.

Main Results:

  • Evidence suggests 5-ASA and PPAR-γ activation can restore insulin sensitivity, improve re-epithelialization, and enhance microcirculation.
  • 5-ASA and TGF-β are implicated in modulating inflammation and pro-inflammatory mediator production.
  • Lower solubility and skin permeability of 5-ASA necessitate advanced formulation strategies.

Conclusions:

  • 5-ASA holds promise as a therapeutic agent for diabetic wounds by targeting key molecular pathways.
  • Activation of PPAR-γ and TGF-β through 5-ASA may offer a novel treatment strategy for DWs.
  • Further research with stabilized formulations is crucial to validate the efficacy of 5-ASA in treating diabetic wounds.
inflammation
oxidation
re-epithelialization